CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 52 enrolled
Drug / intervention
Omeprazole and domperidonedrug
Likely dose
Omeprazole and domperidone 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02685436
NCT02685436Phase 4Completed
CompareCT.gov

Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants

Mansoura University Children Hospital·interventional·Posted Feb 18, 2016·Updated Oct 7, 2019

In Brief

A Phase 4 clinical trial evaluating Omeprazole and domperidone for Gastroesophageal Reflux Disease. Completed, enrolled 52 participants.

Detailed Summary

Wheezy infants were tested for gastro-esophageal reflux disease (GERD) using combined multiple channel intraluminal impedance-pH (MII-pH), esophagogastroduodenoscope (EGD), lipid laden macrophage index and BAL pepsin. Wheezy infants with abnormal MII-pH or reflux esophagitis were given domperidone and omeprazole then re-evaluated for symptoms control and exacerbations recurrence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 18, 2016
Enrollment StartMar 1, 2013
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.4 years ago

Interventions

Omeprazole and domperidonedrug

wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)